Companies Mimedx Group
Mimedx (MDXG): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Mimedx Group’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers63rd pct.Of 18 peer CEOs
CEO pay, last three years
- $20,756,346FY2023
- $1,389,859FY2024
- $7,182,208FY2025
CEO total pay was $7,182,208 in fiscal 2025, up from $1,389,859 in fiscal 2024.
FY2025: salary $768,173 · bonus $0 · stock awards $4,699,000 · option awards $819,422
Executives and directors
Doug Rice · CFORicci Whitlow · COOJoseph Capper · CEOKimberly Maersk-Moller · CCOWilliam Hulse · General CounselCato T. Laurencin · Independent DirectorDorothy E. Puhy · Independent DirectorJames L. Bierman · Independent DirectorK. Todd Newton · Independent DirectorM. Kathleen Behrens · Chair of the BoardMartin P. Sutter · Independent DirectorTiffany P. Olson · Independent DirectorWilliam A. Hawkins · Independent Director
Frequently asked questions
Who was the highest-paid executive at Mimedx Group in fiscal 2025?
As disclosed, Joseph Capper (Chief Executive Officer) was the highest-paid executive at Mimedx Group in fiscal 2025, with total compensation of $7,182,208.
How does Mimedx Group's chief executive pay compare to its disclosed peer group?
As disclosed, Joseph Capper's total compensation ranked at the 63rd percentile of Mimedx Group's disclosed peer group.
What is Mimedx Group's CEO-to-median employee pay ratio?
As disclosed, Mimedx Group's CEO-to-median employee pay ratio was 70:1.
How did shareholders vote on Mimedx Group's executive compensation?
As disclosed, 95.61% of shareholders supported Mimedx Group's executive compensation in the latest say-on-pay vote.
How much does Mimedx Group spend in total on board compensation for fiscal 2025?
As disclosed, Mimedx Group reported total board compensation of $1,674,881 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joseph Capper | $768,173 | $0 | $4,699,000 | $819,422 | $887,800 | $0 | $7,813 | $7,182,208 |
| Chief Executive Officer | ||||||||
| William Hulse IV | 546,000 | 0 | 977,380 | 170,436 | 376,740 | 0 | 74,933 | 2,145,489 |
| General Counsel and Chief Administrative Officer | ||||||||
| William Hulse | 546,000 | 0 | 977,380 | 170,436 | 376,740 | 0 | 74,933 | 2,145,489 |
| General Counsel and Chief Administrative Officer | ||||||||
| Doug Rice | 540,000 | 0 | 966,643 | 168,565 | 372,600 | 0 | 71,921 | 2,119,729 |
| Chief Financial Officer | ||||||||
| Ricci Whitlow | 540,000 | 0 | 966,643 | 168,565 | 372,600 | 0 | 13,135 | 2,060,943 |
| Executive Vice President and Chief Operating Officer | ||||||||
| Kimberly Maersk-Moller | 540,000 | 0 | 966,643 | 168,565 | 372,600 | 0 | 9,041 | 2,056,849 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joseph Capper | $7,182,208 | $1,389,859 | $20,756,346 | ↑ +5,792,349 |
| William Hulse IV | 2,145,489 | 2,401,951 | 1,913,212 | ↓ −256,462 |
| William Hulse | 2,145,489 | — | — | — |
| Doug Rice | 2,119,729 | 2,391,976 | 2,745,075 | ↓ −272,247 |
| Ricci Whitlow | 2,060,943 | 2,294,276 | 3,132,360 | ↓ −233,333 |
| Kimberly Maersk-Moller | 2,056,849 | 3,988,494 | — | ↓ −1,931,645 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
MIMEDX's compensation practices are guided by three overarching principles: attract and retain key talent with specific expertise, align executive pay with company performance, and manage risk.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Willis Towers Watson |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kimberly Maersk-Moller | OPTION | 2025-03-03 | — | — | 36,486 | — | $168,565 |
| Ricci Whitlow | OPTION | 2025-03-03 | — | — | 36,486 | — | 168,565 |
| William Hulse IV | OPTION | 2025-03-03 | — | — | 36,891 | — | 170,436 |
| Ricci Whitlow | RSU | 2025-03-03 | — | — | 45,929 | — | 381,211 |
| Kimberly Maersk-Moller | RSU | 2025-03-03 | — | — | 45,929 | — | 381,211 |
| Joseph Capper | RSU | 2025-03-03 | — | — | 223,268 | — | 1,853,124 |
| Joseph Capper | PSU | 2025-03-03 | 159,478 | 318,955 | — | 574,119 | 2,845,876 |
| William Hulse IV | PSU | 2025-03-03 | 33,171 | 66,342 | — | 119,416 | 591,936 |
| Doug Rice | PSU | 2025-03-03 | 32,807 | 65,613 | — | 118,103 | 585,432 |
| Kimberly Maersk-Moller | PSU | 2025-03-03 | 32,807 | 65,613 | — | 118,103 | 585,432 |
| Ricci Whitlow | PSU | 2025-03-03 | 32,807 | 65,613 | — | 118,103 | 585,432 |
| Joseph Capper | PSU | 2025-03-03 | — | 8 | 177,364 | 30 | 819,422 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kimberly Maersk-Moller | $381,211 | $585,432 | $168,565 | 51.6% |
| Ricci Whitlow | 381,211 | 585,432 | 168,565 | 51.6% |
| William Hulse IV | 0 | 591,936 | 170,436 | 77.6% |
| Joseph Capper | 1,853,124 | 3,665,298 | 0 | 66.4% |
| Doug Rice | 0 | 585,432 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kimberly Maersk-Moller | Option | 29,481 | 8.63 | — |
| Doug Rice | RSU | 32,400 | — | 548,370 |
| Doug Rice | Option | 36,486 | 8.3 | — |
| Ricci Whitlow | Option | 36,486 | 8.3 | — |
| Kimberly Maersk-Moller | Option | 36,486 | 8.3 | — |
| William Hulse IV | Option | 36,891 | 8.3 | — |
| Doug Rice | Option | 47,000 | 6.44 | — |
| Doug Rice | Option | 53,066 | 8.63 | — |
| Ricci Whitlow | Option | 53,066 | 8.63 | — |
| William Hulse IV | Option | 53,655 | 8.63 | — |
| Joseph Capper | Option | 177,364 | 8.3 | — |
| Joseph Capper | Option | 3,000,000 | 3.7 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| M. Kathleen BehrensIndependent · Board Chair · Audit · Nominating Corporate Governance | $132,987 | $168,793 | $0 | $0 | $0 | $301,780 |
| James L. BiermanIndependent · Audit (Chair) | 68,926 | 168,793 | 0 | 0 | 0 | 237,719 |
| K. Todd NewtonIndependent · Compensation (Chair) · Ethics Compliance | 66,786 | 168,793 | 0 | 0 | 0 | 235,579 |
| Cato T. LaurencinIndependent · Ethics Compliance · Nominating Corporate Governance | 58,240 | 168,793 | 0 | 0 | 0 | 227,033 |
| William A. HawkinsIndependent · Ethics Compliance (Chair) | 57,953 | 168,793 | 0 | 0 | 0 | 226,746 |
| Dorothy E. PuhyIndependent · Audit | 55,286 | 168,793 | 0 | 0 | 0 | 224,079 |
| Tiffany P. OlsonIndependent · Compensation | 53,152 | 168,793 | 0 | 0 | 0 | 221,945 |
| Joseph H. CapperEmployee director · Audit · Nominating/Governance | 0 | 0 | 0 | — | 0 | 0 |
| Martin P. SutterIndependent · Compensation · Nominating Corporate Governance (Chair) | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $170,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 21,000 / 16,000 / 12,500 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $493,330 |
| Equity awards (grant-date value) | $1,181,551 |
| All other compensation | $0 |
| Total cost of the board | $1,674,881 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Mimedx as a peer
Companies that benchmark against MDXG
5 companies name MDXG as a compensation peer
- ADMA BIOLOGICS, INC.ADMAFY2025
- Anika Therapeutics, Inc.ANIKFY2025
- Aurinia Pharmaceuticals Inc.AUPHFY2025
- Evolus, Inc.EOLSFY2025
- Organogenesis Holdings Inc.ORGOFY2025
Each company listed discloses MDXG in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MDXG in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CDNA CareDx, Inc.OFIX Orthofix Medical IncXTNT AVITA Medical, Inc.LAB Standard BioTools Inc.BVS Bioventus Inc.VCYT Veracyte, Inc.VCEL Vericel CorporationAXNX Axonics, Inc.OSUR OraSure Technologies, Inc.ORGO Organogenesis Holdings Inc.TCMD Tactile Systems Technology, Inc.OM Outset Medical, Inc.ADMA ADMA Biologics, Inc.ATEC Alphatec Holdings, Inc.ANGO AngioDynamics, Inc.ANIK Anika Therapeutics Integra Life Sciences Holdings CorporationAORT Artivion, Inc.
Peer reciprocity
The companies Mimedx Group names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vericel Corporation | 2025 | Dominick Colangelo | $860,000 | $3,964,630 | $5,456,287 | $860,000 | $11,156,368 |
| 2 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 3 | Adma Biologics, Inc. | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 4 | Standard BioTools Inc. | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 5 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 6 | Orthofix Medical Inc | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 7 | Mimedx Group | 2025 | Joseph Capper | 768,173 | 4,699,000 | 819,422 | 887,800 | 7,182,208 |
| 8 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 9 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 10 | Organogenesis Holdings Inc. | 2025 | Gary Gillheeney | 979,105 | 2,833,330 | 1,380,017 | 1,536,575 | 6,811,754 |
| 11 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 12 | Bioventus Inc. | 2025 | Robert Claypoole | 824,110 | 1,982,530 | 662,949 | 781,256 | 4,299,108 |
| 13 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 14 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 15 | Outset Medical, Inc. | 2025 | Leslie Trigg | 755,166 | 2,197,882 | 0 | 294,515 | 3,255,510 |
| 16 | Anika Therapeutics | 2025 | Stephen Griffin | 500,000 | 1,215,222 | 0 | 0 | 2,033,370 |
| 17 | Avita Medical, Inc. | 2025 | Sean Browne | 624,000 | 588,812 | 0 | 0 | 1,351,676 |
| — | Axonics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Mimedx Group | 115% | not disclosed | No | Willis Towers Watson |
| Adma Biologics, Inc. | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Anika Therapeutics | 100% | PSU 67 · RSU 33 | No | Willis Towers Watson |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| Avita Medical, Inc. | not disclosed | DSU 50 · PSU 50 | not disclosed | not disclosed |
| Axonics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Bioventus Inc. | not disclosed | RSU 49 · PSU 26 · Options 25 | No | Aon plc |
| CareDx, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Organogenesis Holdings Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Orthofix Medical Inc | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Outset Medical, Inc. | 39% | PSU 50 · RSU 50 | Yes — Relative TSR compared to Russell 2000 Medical Device Index | Pearl Meyer |
| Standard BioTools Inc. | 160% | not disclosed | not disclosed | Pearl Meyer |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 95,158,451 | 4,369,645 | 2,223,856 | 95.61% | Passed |
| 2025 | 2025-06-18 | 94,778,256 | 6,924,968 | 209,887 | 93.19% | Passed |
| 2024 | 2024-06-05 | 68,695,869 | 23,968,915 | 1,099,920 | 74.13% | Passed |
| 2023 | 2023-06-13 | 67,923,704 | 8,341,327 | 188,755 | 89.06% | Passed |
| 2022 | 2022-06-07 | 62,182,208 | 30,770,310 | 1,060,849 | 66.9% | Passed |
| 2021 | 2021-05-27 | 51,552,916 | 14,557,553 | 2,695,590 | 77.98% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 95.61%a |
| 2025 | 2025-06-18 | 93.19%b |
| 2024 | 2024-06-05 | 74.13%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 70 : 1 |
|---|---|
| CEO total compensation | $7,182,208 |
| Median employee compensation | $103,278 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dorothy E. Puhy | Director | 2026-06-10 | A | 50,913 | $4 | $185,323 | Common | Form 4 ↗ |
| William A. Hawkins | Director | 2026-06-10 | A | 50,913 | 4 | 185,323 | Common | Form 4 ↗ |
| Tiffany P. Olson | Director | 2026-06-10 | A | 50,913 | 4 | 185,323 | Common | Form 4 ↗ |
| K. Todd Newton | Director | 2026-06-10 | A | 50,913 | 4 | 185,323 | Common | Form 4 ↗ |
| James L. Bierman | Director | 2026-06-10 | A | 50,913 | 4 | 185,323 | Common | Form 4 ↗ |
| Kimberly Maersk-Moller | Chief Commercial Officer | 2026-06-24 | D | 19,820 | 4 | 75,911 | Common | Form 4 ↗ |
| Rice Doug | Chief Financial Officer | 2026-07-02 | D | 12,749 | 4 | 50,359 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (61 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Joseph Capper. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table (2025, 2024 and 2023)” · page 29. As printed: 7,182,208. View filing ↗
- Section 01, William Hulse IV. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table (2025, 2024 and 2023)” · page 29. As printed: 2,145,489. View filing ↗
- Section 01, William Hulse. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table (2025, 2024 and 2023)” · page 29. As printed: 2,145,489. View filing ↗
- Section 01, Doug Rice. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table (2025, 2024 and 2023)” · page 29. As printed: 2,119,729. View filing ↗
- Section 01, Ricci Whitlow. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table (2025, 2024 and 2023)” · page 29. As printed: 2,060,943. View filing ↗
- Section 01, Kimberly Maersk-Moller. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table (2025, 2024 and 2023)” · page 29. As printed: 2,056,849. View filing ↗
- Section 03, Kimberly Maersk-Moller OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Ricci Whitlow OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 03, William Hulse IV OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Ricci Whitlow RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Kimberly Maersk-Moller RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Capper RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Capper PSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards For 2025” · grants of plan-based awards table. View filing ↗
- Section 03, William Hulse IV PSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards For 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Doug Rice PSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards For 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Kimberly Maersk-Moller PSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards For 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Ricci Whitlow PSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards For 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Capper PSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards for 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-29. Section “CEO Pay Ratio”. As printed: 70 : 1. View filing ↗
- Section 08, M. Kathleen Behrens. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 301,780. View filing ↗
- Section 08, James L. Bierman. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 237,719. View filing ↗
- Section 08, K. Todd Newton. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 235,579. View filing ↗
- Section 08, Cato T. Laurencin. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 227,033. View filing ↗
- Section 08, William A. Hawkins. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 226,746. View filing ↗
- Section 08, Dorothy E. Puhy. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 224,079. View filing ↗
- Section 08, Tiffany P. Olson. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 221,945. View filing ↗
- Section 08, Joseph H. Capper. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Martin P. Sutter. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Dorothy E. Puhy 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William A. Hawkins 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tiffany P. Olson 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, K. Todd Newton 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James L. Bierman 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimberly Maersk-Moller 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rice Doug 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-16. Item 5.07 · say-on-pay result. As reported: 95.61% (votes for as printed: 95,158,451). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 93.19% (votes for as printed: 94,778,256). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 74.13% (votes for as printed: 68,695,869). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 493,330 + equity 1,181,551 + all other 0 = 1,674,881, summed across the director compensation table rows.
- Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
- Alphatec Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
- Adma Biologics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Adma Biologics, Inc.'s own proxy. As printed: 10,237,326. View filing ↗
- Standard BioTools Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Standard BioTools Inc.'s own proxy. As printed: 8,823,502. View filing ↗
- Veracyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. View filing ↗
- Orthofix Medical Inc, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical Inc's own proxy. As printed: 7,310,039. View filing ↗
- Mimedx Group (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Mimedx Group's own proxy. As printed: 7,182,208. View filing ↗
- CareDx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
- Organogenesis Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Organogenesis Holdings Inc.'s own proxy. As printed: 6,811,754. View filing ↗
- AngioDynamics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. View filing ↗
- Bioventus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bioventus Inc.'s own proxy. As printed: 4,299,108. View filing ↗
- OraSure Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. View filing ↗
- Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
- Outset Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Outset Medical, Inc.'s own proxy. As printed: 3,255,510. View filing ↗
- Anika Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Anika Therapeutics's own proxy. As printed: 2,033,370. View filing ↗
- Avita Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-23. CEO total compensation as printed in Avita Medical, Inc.'s own proxy. As printed: 1,351,676. View filing ↗
- Section 10a, Organogenesis Holdings Inc. reciprocity. DEF 14A. Organogenesis Holdings Inc. names Mimedx Group in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ADMA Biologics, Inc. reciprocity. DEF 14A. ADMA Biologics, Inc. names Mimedx Group in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Anika Therapeutics reciprocity. DEF 14A. Anika Therapeutics names Mimedx Group in its own disclosed peer group (read from its most recent proxy). View filing ↗